Trends in the management of infectious disease under SARS-CoV-2 era: From pathophysiological comparison of COVID-19 and influenza

doi:10.5501/wjv.v10.i2.62

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6428)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

329

WORD

174

HTML

2735

Figures (1-2)

376

Tables (1-3)

308

Sum=3922

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

370

Download

682

Sum=1052

Publishing Process of This Article

Item

Count

Browse

454

Download

1000

Sum=1454

Mar 25, 2021 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Virol. Mar 25, 2021; 10(2): 62-68
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.62

Table 2 Combination/bundle of the candidate drugs for coronavirus disease 2019 treatment based on the pathophysiological characteristics

Drugs	Pathophysiological characteristics
Antiviral drugs
	Remdesivir for moderate to very severe patients
	Favipiravir for mild to severe patients
Immnomodulators
	Corticosteroids for moderarte to very severe patients
	Tocilizumab for hospitalized COVID-19 patients
	Jak/Stat signaling inhibitors for hospitalized COVID-19 patients
Anticoaglnat drugs
	Heparin
	DOAC

COVID-19: Coronavirus disease 2019; DOAC: Direct oral anticoagulant.

Citation: Seki M. Trends in the management of infectious disease under SARS-CoV-2 era: From pathophysiological comparison of COVID-19 and influenza. World J Virol 2021; 10(2): 62-68
URL: https://www.wjgnet.com/2220-3249/full/v10/i2/62.htm
DOI: https://dx.doi.org/10.5501/wjv.v10.i2.62